SCHEMBL224491

SCHEMBL224491

CC(C)OC(C)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20276399 1.00
SCHEMBL20276345 1.00
SCHEMBL23945 0.86
SCHEMBL16645037 0.86
SCHEMBL15811675 0.83 TSHR (0.33)
SCHEMBL164617 0.81 TSHR (0.32)
SCHEMBL13898732 0.80 TSHR (0.41)
SCHEMBL535995 0.79 TDP1 (0.33)
SCHEMBL2954004 0.79 TDP1 (0.33)
SCHEMBL27981948 0.79 TSHR (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724049-A1 MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF Catalent Ontario Limited (CA) 2026-04-15 EP claimed
US-12343324-B2 Dihydromyricetin hot melt extrusion formulations and methods for forming them THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2025-07-01 US claimed
WO-2024254056-A1 MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF CATALENT ONTARIO LIMITED (CA) 2024-12-12 WO claimed
CN-118201603-A Multiparticulate pharmaceutical compositions 神经中枢制药药物有限责任公司 2024-06-14 CN claimed
EP-4373473-A1 MULTIPARTICULATE PHARMACEUTICAL COMPOSITION Neuraxpharm Pharmaceuticals, S.L. (ES) 2024-05-29 EP claimed
US-20230285352-A1 Dihydromyricetin Hot Melt Extrusion Formulations and Methods for Forming Them THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2023-09-14 US claimed
WO-2023002004-A1 MULTIPARTICULATE PHARMACEUTICAL COMPOSITION LABORATORIOS LESVI, S.L. (ES) 2023-01-26 WO claimed
US-20220280436-A1 SOFTSHELL CAPSULE FORMULATIONS, AND METHODS OF PREPARATION AND USE THEREOF ARES CAPITAL CORPORATION, AS COLLATERAL AGENT 2022-09-08 US claimed
EP-4003310-A1 SOFTSHELL CAPSULE FORMULATIONS, AND METHODS OF PREPARATION AND USE THEREOF R.P. Scherer Technologies, LLC (US) 2022-06-01 EP claimed
WO-2021016305-A1 SOFTSHELL CAPSULE FORMULATIONS, AND METHODS OF PREPARATION AND USE THEREOF R.P. SCHERER TECHNOLOGIES, LLC (US) 2021-01-28 WO claimed
US-20160067071-A1 BIORESORBABLE BIOPOLYMER STENT NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-03-10 US claimed
WO-2015071394-A1 FORMULATION OF SPARINGLY SOLUBLE COMPOUNDS BY HOT-MELT EXTRUSION DSM IP ASSETS B.V. (NL) 2015-05-21 WO claimed
WO-2014176451-A1 BIORESORBABLE BIOPOLYMER STENT TRUSTEES OF TUFTS COLLEGE (US) 2014-10-30 WO claimed
US-7863316-B2 Extended release formulation of Levetiracetam UCB PHARMA S.A. (BE) 2011-01-04 US claimed
US-20070110808-A1 Extended release osmo-microsealed formulation ALEMBIC LIMITED (IN) 2007-05-17 US claimed
EP-1633330-B1 EXTENDED RELEASE OSMO-MICROSEALED FORMULATION ALEMBIC LTD (IN) 2007-04-04 EP claimed
US-20030064101-A1 Floating osmotic device for controlled release drug delivery J.B. CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2003-04-03 US claimed
WO-2003026555-A2 FLOATING OSMOTIC DEVICE FOR CONTROLLED RELEASE DRUG DELIVERY J.B. CHEMICALS & PHARMACEUTICALS LTD. (IN) 2003-04-03 WO claimed
EP-0062226-B1 PROCESS FOR PREPARING WATER-DILUTABLE BINDER SOLUTIONS USING MONO-ALKYL-GLYCOL ETHERS BASF Aktiengesellschaft (DE) 1984-09-19 EP claimed
EP-0062226-A1 Process for preparing water-dilutable binder solutions using mono-alkyl-glycol ethers BASF Aktiengesellschaft (DE) 1982-10-13 EP claimed